AMGN vs MRK
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas.
Side-by-side fundamentals
| Metric | AMGN | MRK | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $439.33 | $152.55 | |
| Market cap as of 2026-08-24 | $237.5B | $376.4B | |
| P/E as of 2026-08-24 | 25.84 | 103.86 | AMGN lower |
| PEG as of 2026-08-24 | 5.48 | 4.91 | MRK lower |
| Net margin as of 2026-08-24 | +22.9% | +4.8% | AMGN higher |
| Gross margin as of 2026-08-24 | +74.3% | +77.3% | MRK higher |
| Operating margin as of 2026-08-24 | +30.3% | +9.6% | AMGN higher |
| ROE as of 2026-08-24 | +89.3% | +17.9% | AMGN higher |
| ROA as of 2026-08-24 | +9.5% | +7.0% | AMGN higher |
| Debt / equity as of 2026-08-24 | 4.90 | 1.07 | MRK lower |
| Revenue growth (YoY) as of 2026-08-24 | +9.1% | +4.6% | AMGN higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +3.1% | AMGN higher |
| Dividend yield as of 2026-08-24 | +3.2% | +2.9% | AMGN higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.41 | 0.22 | |
| 1-year return as of 2026-08-21 close | +48.5% | +77.2% | MRK higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.